- Home
- PTGX vs NVCR Comparison
PTGX vs NVCR Comparison
Compare PTGX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- NVCR
- Stock Information
- Founded
- PTGX 2006
- NVCR 2000
- Country
- PTGX United States
- NVCR Switzerland
- Employees
- PTGX N/A
- NVCR N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- PTGX Health Care
- NVCR Health Care
- Exchange
- PTGX Nasdaq
- NVCR Nasdaq
- Market Cap
- PTGX 3.3B
- NVCR 1.9B
- IPO Year
- PTGX 2016
- NVCR 2015
- Fundamental
- Price
- PTGX $55.32
- NVCR $17.02
- Analyst Decision
- PTGX Strong Buy
- NVCR Buy
- Analyst Count
- PTGX 9
- NVCR 7
- Target Price
- PTGX $67.11
- NVCR $32.43
- AVG Volume (30 Days)
- PTGX 900.6K
- NVCR 1.2M
- Earning Date
- PTGX 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- PTGX N/A
- NVCR N/A
- EPS Growth
- PTGX N/A
- NVCR N/A
- EPS
- PTGX 0.86
- NVCR N/A
- Revenue
- PTGX $207,801,000.00
- NVCR $621,711,000.00
- Revenue This Year
- PTGX N/A
- NVCR $5.44
- Revenue Next Year
- PTGX $53.09
- NVCR $9.05
- P/E Ratio
- PTGX $63.65
- NVCR N/A
- Revenue Growth
- PTGX N/A
- NVCR 18.27
- 52 Week Low
- PTGX $32.50
- NVCR $14.17
- 52 Week High
- PTGX $60.60
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- PTGX 61.17
- NVCR 47.92
- Support Level
- PTGX $49.38
- NVCR $17.33
- Resistance Level
- PTGX $51.51
- NVCR $18.59
- Average True Range (ATR)
- PTGX 2.02
- NVCR 0.69
- MACD
- PTGX 0.02
- NVCR 0.01
- Stochastic Oscillator
- PTGX 75.62
- NVCR 31.44
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.